Full-Time

IT Operations Engineer

Application Support

Posted on 8/19/2025

Point72

Point72

201-500 employees

Global asset manager for long/short equity

Compensation Overview

$160k - $210k/yr

Company Historically Provides H1B Sponsorship

Stamford, CT, USA + 1 more

More locations: New York, NY, USA

In Person

Category
IT & Security (1)
Required Skills
SQL
Linux/Unix
Requirements
  • 7+ years of application support experience within the financial services industry
  • Experience with SQL and other scripting languages
  • Experience working with Unix
  • Prior experience in a team lead or senior role, demonstrating ability to mentor individuals with varying levels of experience
  • Experience managing major outage communications and proven ability to efficiently resolve application issues
  • Strong understanding of order management workflows
  • Commitment to the highest ethical standards
Responsibilities
  • Lead the build out of the Macro trading application support function to provide technical support to our investment professionals
  • Act as a key escalation point for application incident management, leading communications with end-users and senior technology stakeholders on the progress and status of incident resolution
  • Provide cross training to the larger support team on the Macro trading applications and ensure that process documentation is maintained
  • Design and implement robust processes for Macro investment professional application onboarding, including initial setup, access management and user limits administration
  • Implement and regularly review processes, procedures, and policies, and introduce automation to improve team consistency and performance
  • Collaborate with users and technology teams to create project plans
  • Review technology requests and incidents to ensure a high level of internal client service. Produce and report metrics to track performance and trends over time.

Point72 is a global asset management firm offering discretionary long/short equity, systematic, and macro investing, with a growing private markets portfolio. Its products combine active fund management with model-driven approaches across assets and geographies, earning money through management fees and performance-based incentives. The firm differentiates itself through a mix of discretionary trading, systematic methods, macro-focused strategies, a global footprint, and a commitment to ESG practices under Steven A. Cohen. Its goal is to generate superior returns for clients, grow assets, and maintain a culture centered on excellence and continuous learning.

Company Size

201-500

Company Stage

Private

Total Funding

$5.2B

Headquarters

Stamford, Connecticut

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • $89.4B portfolio with NVIDIA, TSM drives AI hardware alpha generation.
  • 59,746 sq ft Hudson Yards lease attracts top quant talent.
  • Private investments yield proprietary insights beyond public markets.

What critics are saying

  • NVIDIA concentration loses 30% on AI cooldown by Q4 2026.
  • SEC fines $500M for insider trading in systematic strategies 2027.
  • Citadel poaches 20% quants, eroding macro edge by Q3 2026.

What makes Point72 unique

  • Point72 Turion invests in SiFive's $400M RISC-V round with NVIDIA.
  • Point72 leads $60M PIPE for Ovid Therapeutics' OV329 GABA inhibitor.
  • Point72 Ventures targets fintech, AI, and enterprise startups exclusively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Fully-paid health care benefits

Generous parental and family leave policies

Mental and physical wellness programs

Volunteer opportunities

Non-profit matching gift program

Support for employee-led affinity groups representing women, minorities and the LGBT+ community

Tuition assistance

A 401(k) savings program with an employer match and more

Company News

Business Insider
Apr 9th, 2026
Hedge funds cut Miami investment staff despite overall growth

Several major hedge funds are reducing their investment staff in Miami despite the city's reputation as a growing finance hub. Eight multistrategy firms — including Citadel, Millennium, Point72 and Balyasny — employed 218 investment professionals in Miami in 2025, down 20 from the previous year, even as their overall investing head count grew by over 11%. Citadel, which moved its headquarters to Miami in 2022, cut 15 investment professionals there whilst adding 77 globally. Millennium reduced its Miami presence from 53 investors to 48 and consolidated from two offices to one. Only ExodusPoint and Walleye increased their Miami investment staff. Growth is instead concentrated in New York, London, Hong Kong and Dubai, according to regulatory filings.

Yardi
Mar 23rd, 2026
Point72 inks lease at Tishman Speyer's Hudson Yards office.

Point72 inks lease at Tishman Speyer's Hudson Yards office. Steve Cohen's Point72 Asset Management is significantly growing its footprint in Hudson Yards with a new lease at The Spiral. According to sources familiar with the transaction, the global alternative investment firm has secured 59,746 square feet of office space in Manhattan, N.Y., within Tishman Speyer's 66-story tower located at 66 Hudson Blvd. This expansion covers the entire 31st floor and a portion of the 21st floor. While the duration of the agreement was not disclosed, the starting rent was reported at $130 per square foot. Although the deal was finalized in December, it was previously unreported until now. In this transaction, Point72 was represented by Neil Goldmacher, Brian Goldman, and Michael Horn of Newmark, while Tishman Speyer was represented in-house by Samantha Augarten and Sam Brodsky. Both firms declined to comment on the specifics of the deal. This move represents a strategic expansion within the immediate neighborhood for Point72, which already maintains a massive presence nearby at 55 Hudson Yards. Before consolidating its operations in this district, Cohen's company occupied 11 floors across two separate buildings at 330 and 510 Madison Ave. Since then, the firm has leased more than 175,000 square feet in the tower that was developed by Related Companies, Oxford Properties Group and Mitsui Fudosan America. With this deal, The Spiral - a 2.85-million-square-foot skyscraper designed by the Bjarke Ingels Group - has reached 98% occupancy. This follows a late 2024 move by private equity giant TPG, which took 301,000 square feet across eight high-rise floors. The building also hosts the U.S. headquarters of HSBC, as well as the likes of Pfizer; Turner Construction; Debevoise & Plimpton LLP; AllianceBernstein; and Marshall Wace. The tower originally opened in 2023. It's situated diagonally across West 34th Street and Bella Abzug Park near the firm's other offices at 55 Hudson Yards. The location also provides a personal convenience for Cohen: With the 7 subway line terminating at Bella Abzug Park, the new lease at The Spiral offers a direct transit route to Citi Field. This connection is timely because Cohen's $8 billion Metropolitan Park proposal was one of three to receive a state gaming license at the end of last year. In partnership with Hard Rock International, Cohen intends to transform 50 acres of parking lots adjacent to the Mets' stadium into a sprawling casino complex. The planned facility includes nearly 300,000 square feet of gaming space; a 1,000-room hotel; a live music venue for 5,650 people; various restaurants; and 25 acres of dedicated green space. Senior Content Writer, CRE News & Market Analysis Drawing on years of intense research in the U.S. commercial real estate market at Yardi Matrix, Diana now applies her expertise as a writer for the CommercialCafe blog. Her articles focus on CRE investment, labor market trends, and technology, and have been picked up by prestigious publications including the New York Times, GlobeSt, The Real Deal, NAIOP, MSN, and Bisnow. March 24, 2026 March 23, 2026 March 20, 2026

Ovid Therapeutics Inc.
Mar 19th, 2026
Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Proceeds expected to support expansion of next-generation GABA-aminotransferase inhibitor, OV329, into tuberous sclerosis complex and infantile spasms Financing led by Point72 with participation from additional investors including Adage Capital Management, ADAR1 Capital Management, Affinity Asset Advisors, LLC, Ally Bridge Group, Balyasny Asset Management, Coastlands Capital, Eventide Asset Management, Janus Henderson Investors and RA Capital Management NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) - Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of $60.0 million to the Company, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about March 19, 2026, subject to

Business Insider
Mar 19th, 2026
Senior leader exits Point72's Cubist after team posts tens of millions in trading losses

Issam Bazzi, a senior leader at Cubist Systematic Strategies, Point72's quant division, is leaving after nearly three years at the $46 billion hedge fund. Bazzi helped lead the buildout of a centralised trading unit at Cubist but his team had been struggling, with losses reaching as much as $70 million this year. The departure follows a leadership shake-up at Cubist last September, when president Denis Dancanet left and was replaced by Geoffrey Lauprete. Bazzi, a Citadel Securities veteran, had negotiated a deal to stay with founder Steve Cohen in October following the changes. Building the centralised trading unit to operate alongside Cubist's independent pods was a key initiative when Dancanet joined in 2020, with the firm spending tens of millions to recruit top talent.

Benzinga
Mar 18th, 2026
Ovid Therapeutics raises $60M to expand GABA inhibitor OV329 into tuberous sclerosis complex

Ovid Therapeutics has raised $60 million in a private placement led by Point72, with participation from existing investors including Adage Capital Management, RA Capital Management and Janus Henderson Investors. The financing is expected to close on 19 March 2026. The biopharmaceutical company is selling 19,154,321 shares of common stock at $2.01 per share, plus pre-funded warrants to purchase up to 10,701,710 additional shares at $2.009 each. The warrants have an exercise price of $0.001 per share and are immediately exercisable. Ovid plans to use the proceeds, combined with existing cash and marketable securities, to expand development of OV329, its next-generation GABA-aminotransferase inhibitor, into tuberous sclerosis complex and infantile spasms.

INACTIVE